Skip to Main Content

Author Details

Bradley J Stish
Mayo Clinic
2007
78
19
PMIDPaper TitleJournal TitlePublished Year
37899635Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.Prostate2024
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
37950310Use of focal radiotherapy boost for prostate cancer: radiation oncologists' perspectives and perceived barriers to implementation.Radiat Oncol2023
37652777A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications.Brachytherapy2023
37696281Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.Lancet Oncol2023
37317888Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.Haematologica2023
37251618Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data.Clin Transl Radiat Oncol2023
37051531Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy.Front Oncol2023
37333345Use of focal radiotherapy boost for prostate cancer and perceived barriers toward its implementation: a survey.medRxiv2023
36475814Safety and Efficacy of CT-Guided Percutaneous Biopsy of Suspicious Subcentimeter Pelvic and Retroperitoneal Lymph Nodes Detected by <sup>11</sup>C-Choline PET in Patients With Prostate Cancer.AJR Am J Roentgenol2023
36511174Improving ultrasound-based brachytherapy needle conspicuity by applying an echogenic coating.Med Phys2023
36427645Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36571507Development and validation of a recursive partitioning analysis-based pretreatment decision-making tool identifying ideal candidates for spine stereotactic body radiation therapy.Cancer2023
36563910Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.Int J Radiat Oncol Biol Phys2023
34509549International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases.Int J Radiat Oncol Biol Phys2022
35789497A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.Prostate2022
35422402Approaching automated applicator digitization from a new angle: Using sagittal images to improve deep learning accuracy and robustness in high-dose-rate prostate brachytherapy.Brachytherapy2022
35850362Stereotactic Body Radiation Therapy for Metastases in Long Bones.Int J Radiat Oncol Biol Phys2022
36845611Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy.Adv Radiat Oncol2022
36070558Cost effectiveness of treatment strategies for high risk prostate cancer.Cancer2022
35995767Outcomes of patients with stage I-II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy.Blood Cancer J2022
36349914Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.J Urol2022
36188436Single and Multifraction Spine Stereotactic Body Radiation Therapy and the Risk of Radiation Induced Myelopathy.Adv Radiat Oncol2022
35878715Radiation Therapy in Oligometastatic Prostate Cancer.Int J Radiat Oncol Biol Phys2022
34890736Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?Radiother Oncol2022
35151922Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation Therapy.Pract Radiat Oncol2022
34876376Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era.Clin Genitourin Cancer2022
35084429Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases.JAMA Oncol2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
32536574Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.Eur Urol Oncol2021
33539968A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.Int J Radiat Oncol Biol Phys2021
33636378Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.Pract Radiat Oncol2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34409210Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.Adv Radiat Oncol2021
34722810Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity.Int J Part Ther2021
34604551Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer.Clin Transl Radiat Oncol2021
34593526Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2021
34273331In Reply to Onal et al.Int J Radiat Oncol Biol Phys2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
34023327The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer.Radiother Oncol2021
33419682The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Eur Urol2021
33268854Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.Prostate Cancer Prostatic Dis2021
32798608Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2021
32960856Androgen Deprivation Therapy Use and Risk of Mild Cognitive Impairment in Prostate Cancer Patients.Alzheimer Dis Assoc Disord2021
32171852Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning.Pract Radiat Oncol2020
33506143Reirradiation for Locoregional Recurrent Breast Cancer.Adv Radiat Oncol2020
31821185Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment: A Population-based Study.Alzheimer Dis Assoc Disord2020
33090219Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.JAMA Oncol2020
32931662Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.Cancer Med2020
  • 1 - 50 of 78

Recommended Authors

Hilary P Bagshaw
Stanford University
Career Start Year 2014
Number of shared co-authors 28
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 23
Soumyajit Roy
Rush University Medical Center
Career Start Year 2013
Number of shared co-authors 30
Andrew Warner
Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 5
Darlene Veruttipong
Stanford University
Career Start Year 2012
Number of shared co-authors 6
Kiri A Sandler
Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 37
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 5
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 21
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 6
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 9
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 33
Nima Aghdam
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 25
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 2
Ananya Choudhury
University of Manchester and The Christie NHS Foundation Trust
Career Start Year 2004
Number of shared co-authors 16
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 22
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 4
Amit Bahl
University Hospitals Bristol and Weston NHS Foundation Trust
Career Start Year 2001
Number of shared co-authors 3
Austin N Kirschner
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 0
Drew Moghanaki
University of California Los Angeles
Career Start Year 2000
Number of shared co-authors 16
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 37
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 8
Constantine A Mantz
University of Chicago
Career Start Year 1997
Number of shared co-authors 29
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 29
Alan W Katz
University of Rochester
Career Start Year 1996
Number of shared co-authors 20
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 29
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 26
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 7
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 14
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 49
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 66

Collaborators

Brian J Davis
Mayo Clinic
Co-authored papers 30
Thomas M Pisansky
Mayo Clinic
Co-authored papers 21
Richard Choo
Mayo Clinic
Co-authored papers 16
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 12
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 10
Amar U Kishan
University of California los angeles
Co-authored papers 9
C Richard Choo
Mayo Clinic
Co-authored papers 9
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 8
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 8
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 8
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 8
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 8
Robert T Dess
University of Michigan ann arbor
Co-authored papers 8
Curtiland Deville
Johns Hopkins University
Co-authored papers 8
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 7
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 7
Brian A Costello
The Mayo Clinic
Co-authored papers 7
Paul C Boutros
University of California los angeles
Co-authored papers 6
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 6
Ryan Phillips
Johns Hopkins University
Co-authored papers 5
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers 5
Michael L Steinberg
University of California los angeles
Co-authored papers 5
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 5
David Jeffrey Demanes
University of California los angeles
Co-authored papers 5
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 5
Trude B Wedde
Oslo University Hospital
Co-authored papers 5
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 5
Chandana A Reddy
Cleveland Clinic
Co-authored papers 5
Avinash Pilar
Princess Margaret Cancer Centre, University of Toronto
Co-authored papers 5
Jay P Ciezki
Cleveland Clinic
Co-authored papers 5
Release 1.2